Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

Official Title: A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients With Nonsense Mutation Cystic Fibrosis

This is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.

ClinicalTrials.gov ID: NCT02139306

Principal Investigator: McColley, Susanna, MD

Study Type: Interventional

Currently Recruiting Patients: No

Contact Information:

Naiomi Nemoto

Clinical Research Coordinator

312.227.6266